Výsledky vyhledávání

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Autor: Suzanne Trudel, Arleigh McCurdy, Molei Fu, Heather J. Sutherland, Martha L Louzada, Michael P. Chu, Darrell J White, Hira S Mian, Rami Kotb, Ibraheem Othman, Moustafa Kardjadj, Engin Gul, Donna E. Reece

Publikováno v: Blood. 140:7306-7307

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6194e5c66d3146968847d303d1f9e3b6
https://doi.org/10.1182/blood-2022-160445

Zobrazit plný text záznamu

Part 1 Results of a Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM)

Autor: Suzanne Trudel, Arleigh McCurdy, Heather J. Sutherland, Martha L Louzada, Christopher P. Venner, Hira S Mian, Rami Kotb, Ibraheem Othman, Fernando Camacho, Engin Gul, Donna E. Reece, Darrell J White, Molei Fu

Publikováno v: Blood. 138:1653-1653

Background: Belantamab mafodotin (belamaf) is a first-in-class antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that has shown clinically meaningful activity as a single agent in relapse/refractory multiple myeloma (RRMM). Pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::016fe6a62318f9464d126d856e8ae3a2
https://doi.org/10.1182/blood-2021-147101

Zobrazit plný text záznamu

P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma

Autor: Suzanne Trudel, Arleigh McCurdy, Christopher P. Venner, Ibraheem Othman, Rami Kotb, Donna E. Reece, Fernando Camacho, Darrell White, Hira S. Mian, Heather J. Sutherland, Martha L Louzada, Engin Gul, Molei Fu

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S162

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::038e744f4dc7579e7eb041a97aa2433f
https://doi.org/10.1016/s2152-2650(21)02349-1

Zobrazit plný text záznamu

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Autor: C. Tom Kouroukis, Darrell White, Nicole B. Laferriere, Michael Sebag, Fernando Camacho, Christopher P. Venner, Rami Kotb, Anthony Reiman, Molei Fu, Nizar J. Bahlis, Julie Stakiw, Arleigh McCurdy, Engin Gul, Donna E. Reece, Jesse Shustik

Publikováno v: Blood. 136:6-6

Lenalidomide (Len) has become the standard first line therapeutic choices for Multiple Myeloma (MM), whether as first line for transplant ineligible patients or as maintenance post transplant. Therapies that are designed to overcome lenalidomide refr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fed9a27b3a1ba7125b1581cff7c933f3
https://doi.org/10.1182/blood-2020-141087

Zobrazit plný text záznamu

A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma

Autor: Michael Sebag, Nizar Bahlis, Christopher P. Venner, Arleigh McCurdy, C. Tom Kouroukis, Jesse Shustik, Darrell J White, Rami Kotb, Julie Stakiw, Nicole B. Laferriere, Tony Reiman, Fernando Camacho, Julia Dobbin, Molei Fu, Engin Gul, Donna E Reece

Publikováno v: Blood. 134:3121-3121

Introduction As lenalidomide (Len) has become an integral part of therapy for newly diagnosed MM patients, most will have been either exposed or refractory to Len at the time of first or second relapse. The monoclonal antibody, Daratumumab, in combin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::34ef25d4fe8c5807cd1828623f754907
https://doi.org/10.1182/blood-2019-124457

Zobrazit plný text záznamu

Growth performance of early-weaned pigs is enhanced by feeding epidermal growth factor-expressing Lactococcus lactis fermentation product

Autor: Molei Fu, Evanna Huynh, Cornelis F M de Lange, D. Wey, Julang Li, Andrea Bedford, Cuilan Zhu

Publikováno v: Journal of biotechnology. 173

We have previously generated epidermal growth factor expressing Lactococcus lactis (EGF-LL) using bioengineering approach, and shown that feeding newly-weaned piglets EGF-LL improves digestive function. To address concerns over the use of genetically

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f2cfd9021e0cebc62f510c94630a4e
https://pubmed.ncbi.nlm.nih.gov/24445174

Zobrazit plný text záznamu

Akademický článek

P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma.

Autor: Trudel, Suzanne, McCurdy, Arleigh, Sutherland, Heather, Louzada, Martha, Venner, Christopher, White, Darrell, Hira Mian, Kotb, Rami, Othman, Ibraheem, Camacho, Fernando, Molei Fu, Engin Gul, Reece, Donna

Publikováno v: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 2, Vol. 21, pS162-S162, 1p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání